Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11926672
APP PUB NO 20210347905A1
SERIAL NO

17127629

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • AMGEN INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Egen, Jackson San Mateo, US 4 17
Garces, Fernando Sherman Oaks, US 12 31
Kim, AeRyon Foster City, US 1 0
Sawant, Deepali Newark, US 2 6
Takenaka, Shunsuke Vancouver, CA 5 15
Yu, Xin Foster City, US 182 1025

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 12, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 12, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 12, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00